22nd May 2012 12:50
22 May 2012
LSE: VER
Vernalis Results of Annual General Meeting
Resolutions
Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.
All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.
Resolution | For (including discretionary votes)* | Against* | Withheld | ||
Ordinary Resolutions (requires 50% majority) | |||||
1. That the audited accounts and related reports of the Directors and auditors for the year ended 31 December 2011 be received | 399,072,328 | (99.99 %) | 2,665 | (0.01 %) | 102 |
2. That the remuneration report contained within the report and accounts for the year ended 31 December 2011 be approved | 399,044,830 | (99.99 %) | 23,237 | (0.01 %) | 7,028 |
3. That Dr A Baxter be re-elected as a director | 399,069,165 | (99.99 %) | 4,993 | (0.01 %) | 937 |
4. That Ms C C Ferguson be re-elected as a director | 399,061,051 | (99.99 %) | 13,102 | (0.01 %) | 942 |
5. That Dr P J Fellner be re-elected as a director | 399,066,142 | (99.99 %) | 8,015 | (0.01 %) | 938 |
6. That Mr I R Garland be re-elected as a director | 399,069,574 | (99.99 %) | 3,396 | (0.01 %) | 2,125 |
7. That Mr N Sheail be re-elected as a director | 399,063,025 | (99.99 %) | 11,115 | (0.01 %) | 955 |
8. That PricewaterhouseCoopers LLP be reappointed auditors and the Directors be authorised to determine their remuneration | 399,058,754 | (99.99 %) | 11,125 | (0.01 %) | 5,216 |
9. That the Directors be authorised to allot shares | 399,062,672 | (99.99 %) | 9,599 | (0.01 %) | 2,824 |
Special Resolutions (requires 75% majority) | |||||
10. That the Directors be authorised to disapply pre-emption rights | 399,059,337 | (99.99 %) | 14,195 | (0.01 %) | 1,563 |
11. That General Meetings, other than Annual General Meetings, may be called on not less than 14 clear days' notice | 399,066,562 | (99.99 %) | 6,840 | (0.01 %) | 1,693 |
Ordinary Resolution (requires 50% majority) | |||||
12. That the adoption of the Vernalis 2012 Value Builder Plan be approved and the Directors be authorised to adopt further plans based on the Vernalis 2012 Value Builder Plan for any overseas employees | 378,940,164 | (94.96 %) | 20,128,021 | (5.04 %) | 6,910 |
*NB: Percentage of votes cast excludes withheld votes
The Company confirms that copies of all resolutions passed at the Annual General Meeting held earlier today, Tuesday 22 May 2012, will be submitted to the National Storage Mechanism (NSM) at www.hemscott.com/nsm.co and will shortly be available for viewing.
- ends -
Enquiries:
Vernalis | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Nomura Code Securities | +44 (0) 20 7776 1200 |
Jonathan Senior, Giles Balleny
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles, Kristin Shine
| |
Taylor Rafferty | +44 (0) 20 7614 2900 |
Rob Newman, Faisal Kanth
|
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as eight programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC